Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G₂

Authors: Brigitte C. Widemann¹; Frank M. Balis²; Aiman Shalabi²; Matthew Boron²; Michelle O'Brien¹; Diane E. Cole²; Nalini Jayaprakash¹; Percy Ivy³; Valerie Castle²; Karin Muraszko²; Christopher L. Moertel⁴; Robert Trueworthy²; Robert C. Hermann²; Ali Moussa³; Stuart Hinton²; Gregory Reaman²; David Poplack²; Peter C. Adamson²

Source: Journal of the National Cancer Institute, Volume 96, Number 20, 20 October 2004 , pp. 1557-1559(3)

Publisher: Oxford University Press

Buy & download fulltext article:

Price: $42.29 plus tax (Refund Policy)

Abstract:

The bacterial enzyme carboxypeptidase G<INF>2</INF> (CPDG<INF>2</INF>) rapidly hydrolyzes methotrexate to inactive metabolites. We administered recombinant CPDG<INF>2</INF> (2000 U) intrathecally to seven cancer patients 3 to 9 hours after they had received an accidental overdose of intrathecal methotrexate (median dose = 364 mg; range = 155–600 mg). Four of the seven patients had cerebrospinal fluid (CSF) exchange to remove methotrexate before CPDG<INF>2</INF> administration. Immediate symptoms of the methotrexate overdoses included seizures (n = 5), coma (n = 2), and cardiopulmonary compromise (n = 2). Before CPDG<INF>2</INF> administration, the median concentrations of methotrexate in CSF were 264 mgr

M (range = 97–510 mgr

M) among patients who had CSF exchange and 8050 mgr

M (range = 2439–16 500 mgr

M) among patients who did not. After intrathecal CPDG<INF>2</INF> administration, methotrexate concentrations in CSF declined by more than 98%. All patients recovered completely from the intrathecal methotrexate overdose except for two patients who had memory impairments. Antibodies to CPDG<INF>2</INF> were not detected in plasma after treatment with intrathecal CPDG<INF>2</INF>. Intrathecal CPDG<INF>2</INF> is well tolerated, rapidly decreases CSF methotrexate concentrations, and appears to be efficacious for treating accidental intrathecal methotrexate overdoses.

Document Type: Research article

DOI: http://dx.doi.org/10.1093/jnci/djh270

Affiliations: 1: Affiliations of authors: Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD (BCW, FMB, MOB, DEC, NJ); Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD (AS, MB, PI); University of Michigan, Ann Arbor (VC, KM); Children's Hospital and Clinics St. Paul, St. Paul, MN (CLM); University of Kansas Medical Center, Kansas City (RT); Northwest Georgia Oncology Centers, PC, Marietta, GA (RCH); Hillcrest Medical Center, Tulsa, OK (AM); Kansas City Cancer Center, Kansas City, MO (SH); Children's Oncology Group, Arcadia, CA (GR); Texas Children's Cancer Center, Houston (DP); Children's Hospital of Philadelphia, Philadelphia, PA (PCA) 2: Affiliations of authors: Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD (BCW, FMB, MOB, DEC, NJ); Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD (AS, MB, PI); University of Michigan, Ann Arbor (VC, KM); Children's Hospital and Clinics St. Paul, St. Paul, MN (CLM); University of Kansas Medical Center, Kansas City (RT); Northwest Georgia Oncology Centers, PC, Marietta, GA (RCH); Hillcrest Medical Center, Tulsa, OK (AM); Kansas City Cancer Center, Kansas City, MO (SH); Children's Oncology Group, Arcadia, CA (GR); Texas Children's Cancer Center, Houston (DP); Children's Hospital of Philadelphia, Philadelphia, PA (PCA) 3: Affiliations of authors: Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD (BCW, FMB, MOB, DEC, NJ); Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD (AS, MB, PI); University of Michigan, Ann Arbor (VC, KM); Children's Hospital and Clinics St. Paul, St. Paul, MN (CLM); University of Kansas Medical Center, Kansas City (RT); Northwest Georgia Oncology Centers, PC, Marietta, GA (RCH); Hillcrest Medical Center, Tulsa, OK (AM); Kansas City Cancer Center, Kansas City, MO (SH); Children's Oncology Group, Arcadia, CA (GR); Texas Children's Cancer Center, Houston (DP); Children's Hospital of Philadelphia, Philadelphia, PA (PCA) 4: Affiliations of authors: Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD (BCW, FMB, MOB, DEC, NJ); Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD (AS, MB, PI); University of Michigan, Ann Arbor (VC, KM); Children's Hospital and Clinics St. Paul, St. Paul, MN (CLM); University of Kansas Medical Center, Kansas City (RT); Northwest Georgia Oncology Centers, PC, Marietta, GA (RCH); Hillcrest Medical Center, Tulsa, OK (AM); Kansas City Cancer Center, Kansas City, MO (SH); Children's Oncology Group, Arcadia, CA (GR); Texas Children's Cancer Center, Houston (DP); Children's Hospital of Philadelphia, Philadelphia, PA (PCA)

Publication date: 2004-10-20

More about this publication?

JNCI - Journal of the National Cancer Institute publishes peer-reviewed original research from around the world and is internationally acclaimed as the source for the most up-to-date news and information from the rapidly changing fields of cancer research and treatment. For the past several years, the JNCI has been ranked as the most-cited original-research cancer journal by the Institute of Scientific Information in its annual Journal Citation Reports. The Journal of the National Cancer Institute's impact factor for 2005, as reported in 2006, was 15.171.